pharmaceuticals

Global Custom Market Research Reports Provider Company

phone

Amarantus Bioscience Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 49
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

Amarantus Bioscience Holdings Inc (Amarantus), formerly Amarantus BioSciences Inc is a biotechnology company that discovers and develops treatments for various therapeutic diseases. The companys therapeutics pipeline products include eltoprazine and mesencephalic-astrocyte-derived neurotrophic factor. Its diagnostics include lymphocyte proliferation test, nuropro blood test and DNA sequencing assay. Amarantus provides DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company also offers phenoguard protein discovery engine platform. It provides products for cell cycle dysfunction, endoplasmic reticulum stress, astrocyte-neuron biology, neurodegeneration and apoptosis, among others. The company develops diagnostics and therapeutics pipeline products for diseases associated with neurodegeneration and apoptosis. Amarantus is headquartered in San Francisco, California, the US.

Amarantus Bioscience Holdings Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13
Venture Financing 15
Amarantus Therapeutics Raises US$1.3 Million In Venture Financing 15
Partnerships 16
Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 16
Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 17
Licensing Agreements 18
Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 18
Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 19
Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 21
Amarantus Bioscience to Enter into Licensing Agreement with University of Leipzig 22
Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 23
Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 24
Equity Offering 25
Amarantus Bioscience to Raise up to USD1.5 Million in Private Placement of 12% Preferred Stock 25
Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 26
Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 27
Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 28
Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 30
Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 31
Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 32
Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 34
Debt Offering 35
Amarantus BioScience Raises USD0.1 Million in Private Placement of 12% Notes Due 2017 35
Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 36
Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For US$1.6 Million 37
Acquisition 39
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 39
Amarantus Bioscience Holdings Inc - Key Competitors 40
Amarantus Bioscience Holdings Inc - Key Employees 41
Amarantus Bioscience Holdings Inc - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Strategy And Business Planning 43
Apr 17, 2017: Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology 43
Corporate Communications 45
Apr 05, 2018: Amarantus Appoints Barney Monte as Interim COO/CFO and Promotes Brian Harvey to Chief Regulatory Advisor 45
Other Significant Developments 46
Dec 01, 2017: Amarantus Provides Comprehensive Corporate Update 46
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List Of Tables

List of Tables
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Key Facts 2
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarantus Bioscience Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13
Amarantus Therapeutics Raises US$1.3 Million In Venture Financing 15
Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 16
Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 17
Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 18
Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 19
Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 21
Amarantus Bioscience to Enter into Licensing Agreement with University of Leipzig 22
Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 23
Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 24
Amarantus Bioscience to Raise up to USD1.5 Million in Private Placement of 12% Preferred Stock 25
Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 26
Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 27
Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 28
Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 30
Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 31
Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 32
Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 34
Amarantus BioScience Raises USD0.1 Million in Private Placement of 12% Notes Due 2017 35
Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 36
Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For US$1.6 Million 37
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 39
Amarantus Bioscience Holdings Inc, Key Competitors 40
Amarantus Bioscience Holdings Inc, Key Employees 41
Amarantus Bioscience Holdings Inc, Other Locations 42
Amarantus Bioscience Holdings Inc, Subsidiaries 42

List Of Figures

List of Figures
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2012 to YTD 2018 10

Amarantus Bioscience Holdings Inc (Amarantus), formerly Amarantus BioSciences Inc is a biotechnology company that discovers and develops treatments for various therapeutic diseases. The companys therapeutics pipeline products include eltoprazine and

View Report

Amarantus Bioscience Holdings Inc (Amarantus), formerly Amarantus BioSciences Inc is a biotechnology company that discovers and develops treatments for various therapeutic diseases. The companys therapeutics pipeline products include eltoprazine and

View Report

Amarantus Bioscience Holdings Inc (Amarantus), formerly Amarantus BioSciences Inc is a biotechnology company that discovers and develops treatments for various therapeutic diseases. The companys therapeutics pipeline products include eltoprazine and

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports